News
ADCT
1.285
-1.15%
-0.015
Weekly Report: what happened at ADCT last week (0831-0904)?
Weekly Report · 2d ago
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
PR Newswire · 6d ago
Weekly Report: what happened at ADCT last week (0824-0828)?
Weekly Report · 08/31 09:57
ADC Therapeutics Balances Earnings Gains With Trial Risks
TipRanks · 08/25 00:11
Weekly Report: what happened at ADCT last week (0817-0821)?
Weekly Report · 08/24 09:58
ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript
The Motley Fool · 08/20 19:49
ADC Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 08/17 13:45
ADC Therapeutics Price Target Cut to $5.00/Share From $10.00 by Guggenheim
Dow Jones · 08/17 13:45
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5
Benzinga · 08/17 13:41
ADC Therapeutics price target lowered to $5 from $10 at Guggenheim
TipRanks · 08/17 11:07
Weekly Report: what happened at ADCT last week (0810-0814)?
Weekly Report · 08/17 09:58
ADC Therapeutics reports Q2 adjusted EPS (11c) vs. (25c) last year
TipRanks · 08/17 08:04
ADC Therapeutics (ADCT) Stock Faces LOTIS 5 Doubts Despite Narrower Loss
Simply Wall St · 08/14 22:44
RBC Capital Remains a Hold on ADC Therapeutics (ADCT)
TipRanks · 08/14 14:25
ADC Therapeutics Reports Q2 2026 Results, Reassesses ZYNLONTA Path
TipRanks · 08/13 13:49
ADC Therapeutics Q2 2026 Earnings Call Transcript
Benzinga · 08/13 13:05
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
NASDAQ · 08/13 12:50
ADC Therapeutics Non-GAAP EPS of -$0.11, revenue of $19.25M beats by $0.35M
Seeking Alpha · 08/13 11:45
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
PR Newswire · 08/13 11:30
ADC Therapeutics Q2 Earnings Preview
Seeking Alpha · 08/12 19:06
More
Webull provides a variety of real-time ADCT stock news. You can receive the latest news about Adc Therapeutics Sa through multiple platforms. This information may help you make smarter investment decisions.
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.